Gellan gum is an approved pharmaceutical excipient with a genuine presence in marketed medicines, not just a topic in research papers. Its pharmaceutical career rests on one property in particular: it is a liquid when you do not want thickness, and a gel when it meets the right conditions.
The mechanism that pharma exploits
Low acyl gellan gum gels in the presence of cations. Physiological fluids — tears, saliva, gastric fluid, intestinal fluid — are all rich in calcium, sodium and potassium.
This means a formulation can be manufactured and filled as a low-viscosity liquid, and will only structure itself after administration, at the target site. That is the definition of an in-situ gelling system, and it is the basis of most pharmaceutical interest in the polymer.
Application 1: Ophthalmic in-situ gelling drops
The best-documented application. The formulation is delivered as eye drops; on contact with the calcium in the tear film, gellan gum forms a gel that increases how long the drug stays on the eye surface.
Three advantages over a conventional pre-thickened gel:
- Longer precorneal residence time than a simple aqueous drop, which improves bioavailability of the active.
- No blurring. Pre-thickened ophthalmic gels are viscous when instilled and blur vision temporarily. An in-situ gelling drop is thin on instillation and thickens afterwards.
- Sterile filtration is possible. This is the under-appreciated manufacturing advantage. A pre-thickened gel is difficult to sterilise by filtration because of its viscosity; a low-viscosity solution of gellan gum can pass through a sterilising filter, and the gel forms later in the eye.
The technology behind the Gelrite trade name is based on this mechanism, and it appears in marketed ophthalmic products.
Application 2: Oral suspensions
In an oral liquid, insoluble drug particles must stay suspended — through manufacture, through the filling line, and through months or years on a pharmacy shelf, where they will be shaken irregularly at best.
Gellan gum provides a yield stress: a threshold stress below which the liquid does not flow. Particles below that threshold stay where they are. The liquid still pours and can still be shaken easily, because the network is weak.
Typical use levels are low, on the order of 0.1–0.3 %, which matters when the formulation also has to taste acceptable.
Application 3: Controlled release and gastroretention
Two further mechanisms are exploited:
- Matrix controlled release. In a tablet or a gel-forming capsule, gellan gum hydrates at the surface to form a gel layer that the drug must diffuse through. The rate of layer formation controls the release profile.
- Gastroretention. A gellan-based system that gels in the stomach can float on gastric contents and remain there longer, extending the absorption window for drugs absorbed in the upper GI tract. This is a well-studied application for in-situ gelling liquids and raft-forming systems.
Application 4: Taste masking and paediatric formulations
Bitter actives are a persistent problem in paediatric medicines. A gel network can reduce contact between the dissolved drug and taste receptors, and it can also be used to structure a chewable or spoonable format that children accept more readily than a tablet.
Formulation considerations
| Consideration | Comment |
|---|---|
| Grade | Low acyl gellan gum is the usual choice; it is the ion-triggered, firm-gelling form |
| Dosage | Low. Typically 0.1–0.5 % for gelling systems, lower for suspension |
| Terminal sterilisation | Heat-stable LA gels can tolerate autoclaving — a significant advantage |
| Aseptic filtration | Viable for low-viscosity solutions before gelation |
| Preservatives | Check compatibility; many preservative systems interact with the gel network |
| Chelating agents | EDTA and citrate bind the calcium the gel needs and will weaken it |
| Ionic actives and buffers | A real trap — see below |
The trap: your own formulation may trigger early gelation
This is the most common pharmaceutical development failure with gellan gum. If the active ingredient, the buffer, or any excipient contributes calcium or other cations, the gum can begin to gel during manufacture rather than after administration.
Practical consequences: a batch that thickens in the mixing vessel, an unfillable suspension, a product that does not meet its viscosity specification.
Practical responses:
- Audit the ionic contribution of every component, including the API itself — many salts are ionic and some supply divalent cations directly.
- Sequence the addition so the gum is hydrated before the ionic components are introduced.
- Use a sequestering agent such as citrate to hold calcium unavailable until administration. This is a standard technique, and it must be titrated rather than guessed.
- Test the final formulation's set behaviour, not just the gum's.
Quality and regulatory requirements
Pharmaceutical grade means a substantially different specification:
- Release against a pharmacopoeial monograph in the applicable edition
- Elemental impurities per USP <232> / <233> and ICH Q3D, with excipient limits derived from permitted daily exposure for the route of administration
- Microbiological quality and, where required, bacterial endotoxins per USP <85>
- Residual solvents per ICH Q3C
- Manufacture under excipient GMP, with audit rights and formal change control
- Regulatory support — typically a Drug Master File or equivalent open part — for the customer's filing
Change control is the requirement that most often surprises food-industry suppliers: a process change that is invisible in a food application can invalidate a customer's regulatory submission.
What to ask a supplier
- Which pharmacopoeial monograph and edition do you release against?
- Can you supply a Drug Master File or equivalent?
- What are your elemental impurity and endotoxin specifications?
- What grade do you recommend for an in-situ gelling ophthalmic application?
- What is your change notification process?
For material and documentation enquiries on gellan gum (E418) across food, cosmetic and higher-specification grades, see Cinogel.
Part of the E418.org gellan gum knowledge base. Pharmaceutical development is governed by medicines regulation; this article is technical background, not regulatory or clinical advice.